Economic Burden of Hidradenitis Suppurativa in Spain

IntroductionHidradenitis suppurativa (HS) is a highly disabling chronic inflammatory disorder affecting up to 1% of the Spanish population. It is a complex disease that requires significant resources and imposes a considerable economic burden. The aim of this study was to assess the economic burden...

ver descrição completa

Detalhes bibliográficos
Autores: Vilarrasa, E, Borrás-Blasco, J, Lobo-Benito, S, Loro-Pérez, M, Núñez-García, MG, Oliva-Moreno, J, Palacios-Martínez, D, Rubial-Bernárdez, F, Ivanova-Markova, Y, Daheron, M, Bellas, J, Martorell, A
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Recursos:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:dnet:r-fisabio___::0b467511c022c618d2516953e649d084
Acesso em linha:https://fisabio.portalinvestigacion.com/publicaciones/20735
https://www.scopus.com/inward/record.uri?eid=2-s2.0-105030725988&doi=10.1007%2fs13555-026-01669-2&partnerID=40&md5=121d37f858ad80b3575234aa749fc772
Access Level:acceso abierto
Palavra-chave:Hidradenitis suppurativa
Economic burden
Spain
Costs
id ES_cb85209c43e9d06d5258cb526aa85bbc
oai_identifier_str oai:dnet:r-fisabio___::0b467511c022c618d2516953e649d084
network_acronym_str ES
network_name_str España
repository_id_str
spelling Economic Burden of Hidradenitis Suppurativa in SpainVilarrasa, EBorrás-Blasco, JLobo-Benito, SLoro-Pérez, MNúñez-García, MGOliva-Moreno, JPalacios-Martínez, DRubial-Bernárdez, FIvanova-Markova, YDaheron, MBellas, JMartorell, AHidradenitis suppurativaEconomic burdenSpainCostsIntroductionHidradenitis suppurativa (HS) is a highly disabling chronic inflammatory disorder affecting up to 1% of the Spanish population. It is a complex disease that requires significant resources and imposes a considerable economic burden. The aim of this study was to assess the economic burden of diagnosed HS in Spain both at patient and population level.MethodsThe study was conducted from a societal perspective using a bottom-up, prevalence-based approach. We evaluated publicly financed direct healthcare costs (consultations, diagnostic tests, inpatient admissions, surgery, comorbidities, treatment), direct nonhealthcare costs (formal and informal care, out-of-pocket expenses), and indirect costs (absenteeism and productivity loss) incurred by patients diagnosed with HS. A sensitivity analysis was conducted to test the uncertainty of the model.ResultsThe mean annual cost of treating all severities of patients with HS in Spain was & euro;39,535.10. The largest cost components across all categories were informal care (46.05%), treatment (18.24%), out-of-pocket expenses (12.76%), loss of work productivity (10.82%), and surgery (5.62%). Moderate and severe patients cost 64.05% (& euro;34,221.92) and 170.53% (& euro;56,432.77) more than mild patients (& euro;20,860.35), respectively. Assuming a prevalence of 1% and a diagnostic rate of 10%, the total economic burden of diagnosed HS in Spain was estimated at & euro;1587 million.ConclusionsHS has a significant economic impact on patients, their families, the healthcare system, and wider society. This is particularly evident among patients with moderate-to-severe HS. To reduce the economic burden and improve quality of life, efforts should be made to prevent the disease from progressing and to ensure that patients remain in the milder stages.ADIS INT LTD2026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/20735https://www.scopus.com/inward/record.uri?eid=2-s2.0-105030725988&doi=10.1007%2fs13555-026-01669-2&partnerID=40&md5=121d37f858ad80b3575234aa749fc772Dermatology and TherapyISSN: 21938210ISSNe: 21909172reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:dnet:r-fisabio___::0b467511c022c618d2516953e649d0842026-06-11T12:45:17Z
dc.title.none.fl_str_mv Economic Burden of Hidradenitis Suppurativa in Spain
title Economic Burden of Hidradenitis Suppurativa in Spain
spellingShingle Economic Burden of Hidradenitis Suppurativa in Spain
Vilarrasa, E
Hidradenitis suppurativa
Economic burden
Spain
Costs
title_short Economic Burden of Hidradenitis Suppurativa in Spain
title_full Economic Burden of Hidradenitis Suppurativa in Spain
title_fullStr Economic Burden of Hidradenitis Suppurativa in Spain
title_full_unstemmed Economic Burden of Hidradenitis Suppurativa in Spain
title_sort Economic Burden of Hidradenitis Suppurativa in Spain
dc.creator.none.fl_str_mv Vilarrasa, E
Borrás-Blasco, J
Lobo-Benito, S
Loro-Pérez, M
Núñez-García, MG
Oliva-Moreno, J
Palacios-Martínez, D
Rubial-Bernárdez, F
Ivanova-Markova, Y
Daheron, M
Bellas, J
Martorell, A
author Vilarrasa, E
author_facet Vilarrasa, E
Borrás-Blasco, J
Lobo-Benito, S
Loro-Pérez, M
Núñez-García, MG
Oliva-Moreno, J
Palacios-Martínez, D
Rubial-Bernárdez, F
Ivanova-Markova, Y
Daheron, M
Bellas, J
Martorell, A
author_role author
author2 Borrás-Blasco, J
Lobo-Benito, S
Loro-Pérez, M
Núñez-García, MG
Oliva-Moreno, J
Palacios-Martínez, D
Rubial-Bernárdez, F
Ivanova-Markova, Y
Daheron, M
Bellas, J
Martorell, A
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Hidradenitis suppurativa
Economic burden
Spain
Costs
topic Hidradenitis suppurativa
Economic burden
Spain
Costs
description IntroductionHidradenitis suppurativa (HS) is a highly disabling chronic inflammatory disorder affecting up to 1% of the Spanish population. It is a complex disease that requires significant resources and imposes a considerable economic burden. The aim of this study was to assess the economic burden of diagnosed HS in Spain both at patient and population level.MethodsThe study was conducted from a societal perspective using a bottom-up, prevalence-based approach. We evaluated publicly financed direct healthcare costs (consultations, diagnostic tests, inpatient admissions, surgery, comorbidities, treatment), direct nonhealthcare costs (formal and informal care, out-of-pocket expenses), and indirect costs (absenteeism and productivity loss) incurred by patients diagnosed with HS. A sensitivity analysis was conducted to test the uncertainty of the model.ResultsThe mean annual cost of treating all severities of patients with HS in Spain was & euro;39,535.10. The largest cost components across all categories were informal care (46.05%), treatment (18.24%), out-of-pocket expenses (12.76%), loss of work productivity (10.82%), and surgery (5.62%). Moderate and severe patients cost 64.05% (& euro;34,221.92) and 170.53% (& euro;56,432.77) more than mild patients (& euro;20,860.35), respectively. Assuming a prevalence of 1% and a diagnostic rate of 10%, the total economic burden of diagnosed HS in Spain was estimated at & euro;1587 million.ConclusionsHS has a significant economic impact on patients, their families, the healthcare system, and wider society. This is particularly evident among patients with moderate-to-severe HS. To reduce the economic burden and improve quality of life, efforts should be made to prevent the disease from progressing and to ensure that patients remain in the milder stages.
publishDate 2026
dc.date.none.fl_str_mv 2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/20735
https://www.scopus.com/inward/record.uri?eid=2-s2.0-105030725988&doi=10.1007%2fs13555-026-01669-2&partnerID=40&md5=121d37f858ad80b3575234aa749fc772
url https://fisabio.portalinvestigacion.com/publicaciones/20735
https://www.scopus.com/inward/record.uri?eid=2-s2.0-105030725988&doi=10.1007%2fs13555-026-01669-2&partnerID=40&md5=121d37f858ad80b3575234aa749fc772
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ADIS INT LTD
publisher.none.fl_str_mv ADIS INT LTD
dc.source.none.fl_str_mv Dermatology and Therapy
ISSN: 21938210
ISSNe: 21909172
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419595364827136
score 15.812429

Registos relacionados